Compare EHTH & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | STTK |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.1M | 119.0M |
| IPO Year | 2006 | 2020 |
| Metric | EHTH | STTK |
|---|---|---|
| Price | $3.63 | $4.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $7.00 | $4.00 |
| AVG Volume (30 Days) | 406.8K | ★ 649.0K |
| Earning Date | 02-25-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $542,951,000.00 | $1,000,000.00 |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $81.78 | ★ N/A |
| Revenue Growth | ★ 16.79 | N/A |
| 52 Week Low | $3.18 | $0.69 |
| 52 Week High | $11.36 | $4.89 |
| Indicator | EHTH | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 61.79 |
| Support Level | $3.74 | $4.25 |
| Resistance Level | $3.92 | $4.80 |
| Average True Range (ATR) | 0.22 | 0.37 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 7.96 | 64.38 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.